Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GRIA4 | P48058 | 16/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13255837 | 1.00 | CYP2C19 (0.49) | CYP2C19GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL6563345 | 0.95 | CYP2C19 (0.53) | CYP2C19GRIA4GRIA1GRIA2KMT2A | |
| SCHEMBL5187957 | 0.90 | GRIA4 (0.56) | CYP2C19GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5187868 | 0.90 | CYP2C19 (0.45) | CYP2C19GRIA4KMT2A | |
| SCHEMBL5187414 | 0.89 | CYP2C19 (0.41) | CYP2C19GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5187315 | 0.89 | GRIA2 (0.57) | CYP2C19GRIA4GRIA1GRIA2GRIA3 | |
| SCHEMBL5188496 | 0.89 | CYP2C19 (0.48) | CYP2C19GRIA4 | |
| SCHEMBL14394435 | 0.89 | CYP2C19 (0.48) | CYP2C19GRIA4GRIA1KMT2A | |
| SCHEMBL3703930 | 0.88 | CYP2C19 (0.47) | CYP2C19GRIA4GRIA1GRIA2KMT2A | |
| SCHEMBL3703932 | 0.88 | CYP2C19 (0.47) | CYP2C19GRIA4GRIA1GRIA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010087982-A1 | GLUR2 RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
| US-20090270508-A1 | GluR2 receptor modulators | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270508-A1 | GluR2 receptor modulators | GRM2, GRIK2, GRIN2A | CYP2C19 4612/4885GRIA4 16/4885GRIA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.